Effect of an oral complementary medicine combination for symptomatic knee osteoarthritis: A double-blind, randomized, placebo-controlled trial
Osteoarthritis and Cartilage · 2026
DOI: 10.1016/j.joca.2026.06.008 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Osteoarthritis and Cartilage, 2026. Verfasst von Shiwen Yuan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Musculoskeletal Research Centre, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Rheumato…. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Plant Extracts, Sulfones, Complementary Therapies. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
OBJECTIVE: Many individuals use complementary medicine therapies for osteoarthritis, despite limited scientific supporting evidence. These therapies have demonstrated anti-inflammatory, antioxidative, and chondroprotective effects via different molecular pathways, suggesting potential therapeutic benefits. This trial aimed to evaluate the efficacy and safety of a novel oral complementary medicine combination in adults with symptomatic knee osteoarthritis at 12 weeks. DESIGN: The 12-week, double-blind, randomized, placebo-controlled ATLAS trial was conducted in Australia from July 2024 to April 2025 (ACTRN12623000380695). Eligible participants were aged ≥40 years with symptomatic knee osteoarthritis and radiographic Kellgren-Lawrence grade ≥2. Participants were randomized 1:1 to receive the complementary medicine combination, comprising a total daily dose of Boswellia serrata extract 250 mg, pine bark extract 100 mg, methylsulfonylmethane 1500 mg, curcumin 500 mg, and piperine 5 mg, or placebo. The primary outcome was the 12-week change in knee pain (0-100 mm visual analogue scale (VAS)). A 95% confidence interval excluding differences >18 mm between groups was interpreted as the absence of a clinically meaningful difference. Harms were monitored weekly. RESULTS: Eighty-four participants were recruited (mean [SD], age 63.7 [8.0] years, BMI 29.0 [5.5] kg/m2), and 57% were female. At 12-weeks, both groups (intention-to-treat population: complementary medicine, n=42; placebo, n=41) showed a decrease in VAS pain (least squares means: complementary medicine 20.1 mm vs placebo 20.3 mm), however with no difference between groups: 0.16 mm (95% CI -6.81 to 7.12). The safety profile of experiencing any AE was similar between groups (risk difference, -3.4% [95% CI -24.8-17.9%]); and most adverse events were mild or moderate. Four participants experienced serious adverse events, unrelated to the treatment. CONCLUSIONS: The complementary medicine combination was not superior to placebo for improving pain over 12 weeks, and the evidence does not support the use of this combination to treat people with symptomatic knee osteoarthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sydney Musculoskeletal Research Centre, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Rheumatology Department, Guangzhou First People's Hospital, Guangzhou, Guangdo…
- Sydney Musculoskeletal Research Centre, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Rheumatology Department, Royal North Shore Hospital, Northern Sydney Local Hea…
- Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; Research Unit of Rheumatology, Department of Clinical Research, University of Sout…
- Faculty of Medicine and Health, Sydney Pharmacy School, University of Sydney, Sydney, NSW, Australia. Electronic address: joanna.harnett@sydney.edu.au.
- Faculty of Medicine and Health, Sydney Pharmacy School, University of Sydney, Sydney, NSW, Australia. Electronic address: andrew.mclachlan@sydney.edu.au.
- Northern Sydney Local Health District Executive, Royal North Shore Hospital, St Leonards, NSW, Australia. Electronic address: venkatesha.venkatesha@health.nsw.gov.au.
Förderung
- National Health and Medical Research Council
Zitieren
APA
Yuan, S., Liu, X., Bracken, K., Christensen, R., Deveza, L. A., Collins, S., Harnett, J. E., McLachlan, A. J., Robbins, S., Venkatesha, V., Bowden, J. L., & Hunter, D. J. (2026). Effect of an oral complementary medicine combination for symptomatic knee osteoarthritis: A double-blind, randomized, placebo-controlled trial. Osteoarthritis and Cartilage. https://doi.org/10.1016/j.joca.2026.06.008
Vancouver
Yuan S, Liu X, Bracken K, Christensen R, Deveza LA, Collins S, et al. Effect of an oral complementary medicine combination for symptomatic knee osteoarthritis: A double-blind, randomized, placebo-controlled trial. Osteoarthritis and Cartilage. 2026. doi:10.1016/j.joca.2026.06.008
BibTeX
@article{Yuan2026,
author = {Yuan, Shiwen and Liu, Xiaoqian and Bracken, Karen and Christensen, Robin and Deveza, Leticia Alle and Collins, Simone and Harnett, Joanna E and McLachlan, Andrew J and Robbins, Sarah and Venkatesha, Venkatesha and Bowden, Jocelyn L and Hunter, David J},
title = {Effect of an oral complementary medicine combination for symptomatic knee osteoarthritis: A double-blind, randomized, placebo-controlled trial},
journal = {Osteoarthritis and Cartilage},
year = {2026},
doi = {10.1016/j.joca.2026.06.008}
}
EUVIMED